Chargement en cours...
COMBINATION THERAPY WITH GLP-1 RECEPTOR AGONIST AND SGLT2 INHIBITOR
The SGLT2 inhibitors (SGLTi) and glucagon-like-1 receptor agonists (GLP-1 RAs) effectively reduce HbA1c, but via very different mechanisms, making them an effective duet for combination therapy. Recently, drugs in both of these antidiabetic classes have been shown to reduce cardiovascular events, mo...
Enregistré dans:
| Publié dans: | Diabetes Obes Metab |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5643008/ https://ncbi.nlm.nih.gov/pubmed/28432726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12982 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|